Cotargeting survival signaling pathways in cancer (Journal of Clinical Investigation (2008) 118, (3003-3006) DOI: 10.1172/JCI36898);Cotargeting survival signaling pathways in cancer

Journal of Clinical Investigation

Volumn 118, Issue 9, 2008, Pages 3003-3006

  Grant, Steven ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Goodwin Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SORAFENIB; TIPIFARNIB;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; DRUG TARGETING; ENZYME ACTIVATION; FEEDBACK SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NEOPLASM; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 51349098887     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36898E1     Document Type: Erratum

References (20)

1. Van Etten, R.A. 2007. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J. Exp. Med. 204:461-465.
2. Cantley, L.C., and Neel, B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96:4240-4245.
3. Weinstein, I.B., and Joe, A.K. 2006. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3:448-457.
4. Stommel, J.M., et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 318:287-290.
5. McCubrey, J.A., et al. 2006. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46:249-279.
6. Sebolt-Leopold, J.S., and Herrera, R. 2004. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer. 4:937-947.
7. Manning, B.D., and Cantley, L.C. 2007. AKT/PKB signaling: navigating downstream. Cell. 129:1261-1274.
8. Bjornsti, M.A., and Houghton, P.J. 2004. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer. 4:335-348.
9. O'Reilly, K.E., et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
10. Sarbassov, D.D., et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22:159-168.
11. Mitsiades, N., et al. 2002. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 99:4079-4086.
12. Kinkade, C.W., et al. 2008. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118:3051-3064.
13. Ley, R., et al. 2004. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J. Biol. Chem. 279:8837-8847.
14. Carracedo, A., et al. 2008. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118:3065-3074.
15. She, Q.B., et al. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 8:287-297.
16. Qi, X.J., Wildey, G.M., and Howe, P.H. 2006. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J. Biol. Chem. 281:813-823.
17. Mathew, R., Karantza-Wadsworth, V., and White, E. 2007. Role of autophagy in cancer. Nat. Rev. Cancer. 7:961-967.
18. Kaarbo, M., Klokk, T.I., and Saatcioglu, F. 2007. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 29:1227-1238.
19. Shen, M.M., and Abate-Shen, C. 2007. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 67:6535-6538.
20. Datta, S.R., Brunet, A., and Greenberg, M.E. 1999. Cellular survival: a play in three Akts. Genes Dev. 13:2905-2927.